Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicinClemens Unger, Brigitte Häring, Michael Medinger, et al.
BMC Cancer|July 12, 2014
Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisKlaus Mross, Martin Büchert, Annette Frost, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancerStephan Mielke, Alex Sparreboom, Seth M Steinberg, et al.
Cancer Chemotherapy and Pharmacology|August 24, 2004
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose studyKlaus Mross, Bernward Niemann, Ulrich Massing, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2006
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropeniaTristan M Sissung, Klaus Mross, Seth M Steinberg, et al.
Pathology Oncology Research : POR|February 24, 2010
c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysisMichael Medinger, Manuela Kleinschmidt, Klaus Mross, et al.
Anti-Cancer Drugs|November 5, 2003
Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 hStephan Mielke, Klaus Mross, Thomas A Gerds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusionsHans Gelderblom, Klaus Mross, Albert J ten Tije, et al.
International Journal of Clinical Pharmacology and Therapeutics|May 8, 2014
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging dataKlaus Mross, Max Scheulen, Dirk Strumberg, et al.
Onkologie|December 8, 2007
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II studySimone Steinbild, Jann Arends, Michael Medinger, et al.
Pageof 4